Short Bowel Syndrome Market — Global Industry Insights, Trends, Outlook, and OppPosted by priya saraf on June 18th, 2019 Short bowel syndrome (SBS) is a malabsorption syndrome caused as a result of the small intestine not functioning efficiently. One of the prime symptoms of short bowel syndrome is diarrhea, which leads to dehydration, malnutrition, and unexplained and drastic weight loss in most the patients. If left untreated, SBS can lead to complication such as anemia and kidney stones. The main causes of short bowel syndrome in children is damaged intestinal tissue, blockage or obstruction in intestine, gastroschisis, and rotation of the midgut also known as malrotation and in grown-ups. Short bowel syndrome is detected in Crohn’s disease, radiation enteritis, and mesenteric ischemia. This syndrome usually occurs in cases due to surgical elimination of major portion of small intestine Request A Sample Copy: http://bit.ly/2KoSb6S GLP-2 drug class dominates the leading markets in North America and Europe The global short bowel syndrome market is segmented on the basis of drug class and geography. On the basis of drug class, the market is divided into GLP-2, growth hormone, glutamine and others. Increasing prescription of Gattex Therapy for Short Bowel Syndrome in North America creates a highly lucrative prospect for growth Regional segmentation of the short bowel syndrome market by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America accounts for the largest share in global market, mainly due to presence of major players and early adoption of advanced medical technologies in countries such as the U.S. and Canada. According to National Institute of Diabetes and Digestive and Kidney Disease, in 2008, there were more than 2,000 intestinal transplantations performed in the U.S., out of which 75% population was of the age group of 18-20 years. These numbers are expected to increase year on year, which would inadvertently fuel growth of the short bowel syndrome market. Key players in the global short bowel syndrome market Key players operating the short bowel syndrome market include Ardelyx, Inc., Emmaus Life Sciences, Inc., GLyPharma Therapeutic, Inc., Merck KGaA, Naia Pharmaceuticals, Inc., Nutrinia Ltd., OxThera, Sancilio & Company, Inc., Shire plc, and Zealand Pharma A/S. Major companies in the short bowel syndrome industry are constantly working towards introducing innovative products and lowering production costs in order to enhance profitability. For instance, Nutrinia Ltd. plans to begin a critical clinical trial on a drug for short bowel syndrome, which will aid thousands of patients globally by reducing their dependence on parenteral nutrition is the major cause of liver infection. Click To Read More On Short Bowel Syndrome Market About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr.Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Like it? Share it! More by this author |